ID   COLO 677
AC   CVCL_1862
SY   COLO-677; COLO #677; COLO677; Colorado 677
DR   CLO; CLO_0002550
DR   CLDB; cl837
DR   CLDB; cl838
DR   BioSample; SAMN03151910
DR   Cosmic; 753542
DR   DSMZ; ACC-248
DR   DSMZCellDive; ACC-248
DR   ECACC; 93072109
DR   GEO; GSM784242
DR   IARC_TP53; 21233
DR   PharmacoDB; COLO677_225_2019
DR   Progenetix; CVCL_1862
DR   Wikidata; Q54814130
RX   CelloPub=CLPUB00604;
RX   PubMed=11668190;
RX   PubMed=20143388;
RX   PubMed=32123307;
CC   Problematic cell line: Contaminated. Shown to be a RPMI-8226 derivative (PubMed=20143388). Originally thought to originate from the lymph nodes of a 50 year old male patient with a small cell lung carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00299.
CC   Characteristics: Produces IgG lambda (from parent cell line).
CC   Doubling time: ~40 hours (DSMZ=ACC-248).
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (CelloPub=CLPUB00604).
CC   Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (CelloPub=CLPUB00604).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: DSMZ; ACC-248; true.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 15,19
ST   D19S433: 14
ST   D21S11: 28,29
ST   D2S1338: 20
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 19
ST   Penta D: 3,11
ST   Penta E: 16,17
ST   TH01: 8
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0014 ! RPMI-8226
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 30
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).